PHARMACEUTICAL INDUSTRY DEVELOPMENT: KEY POLICY INSTRUMENTS IN CHINA

Author:

Honcharenko Daria1ORCID

Affiliation:

1. Kharkiv Medical Academy of Postgraduate Education

Abstract

The article provides an overview of programs, plans, tools of scientific and technological, innovation and industrial policy aimed at creating and producing new drugs in China; it is substantiated that the Chinese government uses an integrated approach in the implementation of mechanisms to protect and strengthen the pharmaceutical industry. It is demonstrated that the Chinese government provides business support in the form of subsidies, tax incentives, the creation of special zones for the development of high-tech industries, and helps to attract foreign direct investment in contract manufacturing and research and development, accompanied by technology transfer; through the public procurement system, a program for the development of endogenous innovations is implemented through the provision of price preferences, and advanced foreign technologies are involved. State support contributed to an increase in the level of localization of production and an increase in the number of jobs, an increase in the added value of production and the competitiveness of the pharmaceutical industry, the formation of scientific and technical competencies and the development of technologies, the creation of objects of intellectual property rights. The Chinese model of investment and innovative development, relying on the use of external technological, production, human resources, has made it possible to form a high-tech pharmaceutical sector capable of producing endogenous innovations. Given the objectives of the policy documents, Chinese enterprises are encouraged to invest in other countries in the interests of the development of Chinese pharmaceuticals.

Publisher

OU Scientific Route

Reference35 articles.

1. World Economic Outlook Update (2020). A Crisis Like No Other, An Uncertain Recovery. Available at: https://www.imf.org/en/Publications/WEO/Issues/2020/06/24/WEOUpdateJune2020

2. Schwarz, P. (2020). European Union to spend half a trillion euros on imperialist interests in coronavirus bailout. World Socialist Web Site. Available at: https://www.wsws.org/en/articles/2020/04/13/euro-a13.html

3. Science and Engineering (2020). The State of U.S. Available at: https://ncses.nsf.gov/pubs/nsb20201/data

4. The Indian pharmaceutical industry – the way forward (2019). Mumbai. Available at: https://www.ipa-india.org/static-files/pdf/publications/position-papers/2019/ipa-way-forward.pdf

5. Ni, J., Zhao, J., Ung, C. O. L., Hu, Y., Hu, H., Wang, Y. (2017). Obstacles and opportunities in Chinese pharmaceutical innovation. Globalization and Health, 13 (1). doi: http://doi.org/10.1186/s12992-017-0244-6

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3